top of page

Pipeline

Advancing a Robust Portfolio Across Immunotherapy and Regenerative Medicine.

At JY BioMed, we are advancing a diversified pipeline of investigational programs targeting oncology, regenerative health, and immune modulation. Our focus is on building platforms that are scalable, scientifically rigorous, and globally compliant. Each program is carefully designed to address significant areas of unmet medical need through innovative approaches in cell therapy, exosome therapeutics, and targeted biologics. Our pipeline spans from discovery through early clinical development, with a strong commitment to regulatory excellence and scientific validation.

DC001

Velmira®

Solid tumors

Oncology: Solid tumors

Pre-clinical

Regulatory Disclaimer

The pipeline programs described herein are at various stages of development. Except for the UC-MSC platform currently under Phase 1 clinical evaluation in Taiwan, all other programs remain under preclinical investigation and have not been approved for clinical or commercial use.

bottom of page